Literature DB >> 12052462

Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice.

L Stabnov1, Y Kasukawa, R Guo, Y Amaar, J E Wergedal, D J Baylink, S Mohan.   

Abstract

Insulin-like growth factor-1 (IGF-1) increases both bone formation and bone resorption processes. To test the hypothesis that treatment with an antiresorber along with IGF-1, during the pubertal growth phase, would be more effective than IGF-1 alone to increase peak bone mass, we used an IGF-1 MIDI mouse model, which exhibits a >60% reduction in circulating IGF-1 levels. We first determined an optimal IGF-1 delivery by evaluating IGF-1 administration (2 mg/kg body weight/day) by either a single daily injection, three daily injections, or by continuous delivery via a minipump during puberty. Of the three regimens, the three daily IGF-1 injections and IGF-1 through a minipump produced a significant increase in total body bone mineral density (BMD) (6.0% and 4.4%, respectively) and in femoral BMD (4.3% and 6.2%, respectively) compared with the control group. Single subcutaneous (s.c.) administration did not increase BMD. We chose IGF-1 administration three times daily for testing the combined effects of IGF-1 and alendronate (100 microg/kg per day). The treatment of IGF-1 + alendronate for a period of 2 weeks increased total body BMD at 1 week and 3 weeks after treatment (21.1% and 20.5%, respectively) and femoral BMD by 29% at 3 weeks after treatment. These increases were significantly greater than those produced by IGF-1 alone. IGF-1, but not alendronate, increased bone length. IGF-1 and/or alendronate increased both periosteal and endosteal circumference. Combined treatment caused a greater increase in the total body bone mineral content (BMC) and periosteal circumference compared with individual treatment with IGF-1 or alendronate. Our data demonstrate that: (1) inhibition of bone turnover during puberty increases net bone density; and (2) combined treatment with IGF-1 and alendronate is more effective than IGF-1 or alendronate alone in increasing peak bone mass in an IGF-1-deficient MIDI mouse model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052462     DOI: 10.1016/s8756-3282(02)00738-x

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  12 in total

1.  Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms.

Authors:  Subburaman Mohan; Charmaine Richman; Rongqing Guo; Yousef Amaar; Leah Rea Donahue; Jon Wergedal; David J Baylink
Journal:  Endocrinology       Date:  2003-03       Impact factor: 4.736

2.  Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo.

Authors:  Xuezhong Qin; Jon E Wergedal; Mark Rehage; Kiet Tran; Jacqueline Newton; Paggie Lam; David J Baylink; Subburaman Mohan
Journal:  Endocrinology       Date:  2006-08-31       Impact factor: 4.736

Review 3.  The somatotropic axis and aging: Benefits of endocrine defects.

Authors:  Andrzej Bartke; Edward O List; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2016-02-16       Impact factor: 2.372

Review 4.  Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis.

Authors:  Eben G Estell; Clifford J Rosen
Journal:  Nat Rev Endocrinol       Date:  2020-11-04       Impact factor: 43.330

Review 5.  Regulation of skeletal growth and mineral acquisition by the GH/IGF-1 axis: Lessons from mouse models.

Authors:  Shoshana Yakar; Olle Isaksson
Journal:  Growth Horm IGF Res       Date:  2015-09-28       Impact factor: 2.372

Review 6.  Insulin-like growth factors: actions on the skeleton.

Authors:  Shoshana Yakar; Haim Werner; Clifford J Rosen
Journal:  J Mol Endocrinol       Date:  2018-04-06       Impact factor: 5.098

7.  Disruption of four-and-a-half LIM 2 decreases bone mineral content and bone mineral density in femur and tibia bones of female mice.

Authors:  K E Govoni; D J Baylink; J Chen; S Mohan
Journal:  Calcif Tissue Int       Date:  2006-08-15       Impact factor: 4.333

8.  Evidence that sensitivity to growth hormone (GH) is growth period and tissue type dependent: studies in GH-deficient lit/lit mice.

Authors:  Yuji Kasukawa; David J Baylink; Rongqing Guo; Subburaman Mohan
Journal:  Endocrinology       Date:  2003-09       Impact factor: 4.736

9.  Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate.

Authors:  Y Matsumoto; Y Mikuni-Takagaki; Y Kozai; K Miyagawa; K Naruse; H Wakao; R Kawamata; I Kashima; T Sakurai
Journal:  Osteoporos Int       Date:  2009-03-12       Impact factor: 4.507

10.  Growth hormone regulates the balance between bone formation and bone marrow adiposity.

Authors:  Philip J Menagh; Russell T Turner; Donald B Jump; Carmen P Wong; Malcolm B Lowry; Shoshana Yakar; Clifford J Rosen; Urszula T Iwaniec
Journal:  J Bone Miner Res       Date:  2010-04       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.